A study showed plasma-derived exosome-loaded QCT nanoparticles showed improved bioavailability with therapeutic effect in Alzheimer’s disease by inhibiting cyclin-dependent kinase 5 (CDK5) facilitated phosphorylation of protein Tau (45). This evidence concerns the gene CDK5 and Alzheimer disease.